Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Ustekinumab might work for severe psoriasis, but more research is needed to be sure.

Certain factors like being female, having high cholesterol, using Medicaid, and previous non-biologic treatments increase the risk of multiple biologic failures in psoriasis patients.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.

Patients with alopecia areata feel less regret about treatment decisions when they are involved in the decision-making process.

Biologic treatments for Crohn's disease and ulcerative colitis can cause skin problems, and doctors should adjust treatment if these occur.

Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.

Methotrexate for rheumatoid arthritis often causes side effects like diarrhea, fatigue, and hair loss, especially at higher doses.

Traditional treatment for pediatric alopecia areata is most effective and should be first choice.

Collaborative care between physicians and pharmacists improved medication management for rheumatoid arthritis without raising costs.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Hidradenitis Suppurativa is a chronic skin condition best treated early with surgery for better outcomes and less recurrence.

Sex and race affect immune responses and treatment outcomes in Hidradenitis suppurativa.

Cataract surgery in Europe varies in frequency and cost between countries.

Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.

Platelet-rich plasma treatment is not very effective for chronic severe alopecia areata.

The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.

Dupilumab users have a higher risk of developing alopecia areata.

Psoriasis involves an imbalance between certain immune cells, and targeting these could help restore skin health.

Current skin substitutes help heal severe burns but don't fully replicate natural skin features.

Improving education, training, and access to affordable treatments is crucial for better managing inflammatory skin diseases in Latin America.

IBD treatment is complex and requires personalized approaches due to varying patient responses.

Cataract surgery guidelines vary across Europe, and generic finasteride sales for hair loss have grown due to pill splitting.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Regenerative medicine could revolutionize aesthetic surgery, but needs careful validation and ethical use.

Hormone therapy is safe and effective for transgender adults, but requires regular monitoring and mental health support.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.